Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Vistagen Therapeutics, Inc. (VTGN)
|
Add to portfolio |
|
|
|
| Price: |
$1.97
| | Metrics |
| OS: |
9.36
|
M
| |
-677
|
% ROE
|
| Market cap: |
$18.4
|
M
| |
-2524
|
% ROIC
|
|
Net cash:
|
$9.62
|
M
| |
$1.03
|
per share
|
|
EV:
|
$8.82
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($46.4)
|
M
| |
|
|
|
EBIT
|
($46.5)
|
M
| |
|
|
| EPS |
($2.82)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Mar-31-23 | Mar-31-22 | Mar-31-21 | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 |
| Revenues | -0.2 | 1.1 | 1.1 | 0.0 | 0.0 | 0.0 | 1.3 | 0.0 |
| Revenue growth | -120.5% | 1.8% | | | | -100.0% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | -0.2 | 1.1 | 1.1 | 0.0 | 0.0 | 0.0 | 1.3 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | | | | 100.0% | |
| Research and development | 44.4 | 35.4 | 11.9 | 13.4 | 17.1 | 7.8 | 5.2 | 3.9 |
| General and administrative | 14.7 | 13.5 | 7.1 | 7.4 | 7.5 | 6.4 | 6.3 | 13.9 |
| EBIT | -59.3 | -47.8 | -17.9 | -20.8 | -24.6 | -14.2 | -10.2 | -17.9 |
| EBIT margin | 26074.8% | -4308.7% | -1646.1% | | | | -819.9% | |
| Pre-tax income | -59.2 | -47.8 | -17.9 | -20.8 | -24.6 | -14.3 | -10.3 | -47.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | | | | | | |
| Net income | -59.2 | -48.7 | -42.3 | -22.0 | -25.7 | -15.6 | -11.6 | -51.4 |
| Net margin | 26065.9% | -4392.4% | -3884.3% | | | | -929.9% | |
| |
| Diluted EPS | ($8.51) | ($7.38) | ($0.49) | ($0.50) | ($0.90) | ($1.12) | ($1.54) | ($29.08) |
| Shares outstanding (diluted) | 7.0 | 6.6 | 86.1 | 43.9 | 28.6 | 13.9 | 7.5 | 1.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|